glp 1 hfpef Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document - Monzo - 2025 Heart failure with preserved ejection
Description
For weight management, lack of at least 5% weight loss by 12 weeks at the maintenance dose warrants discussion about alternative strategies or dose optimization
February 16, 2025 10:00 View More GLP-1 Agonists: The Medical Revolution Beyond Weight Loss In this podcast episode, McCall McPherson, a medical professional from the Modern Thyroid Clinic, explores the benefits of GLP-1 agonists, originally developed for diabetes
Moreover, it is involved in the protective effect of myocardial cells after myocardial ischemia
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
The most commonly reported adverse effects are gastrointestinal in nature
